GSK’s £400 Million Investment Signals a Major Boost for UK Life Sciences

GlaxoSmithKline (GSK) has confirmed a £400 million investment over the next three years to build a new flagship R&D centre on the Cambridge Biomedical Campus. The 300,000 sq ft site will house more than 1,000 scientists and focus on oncology, respiratory disease, hepatology, vaccines, and HIV research.

It's one of the most significant life sciences announcements of the year, and it comes with a real story for the UK healthcare workforce: not just where new roles are being created, but where existing ones are moving from.

 

GSK's new centre will sit within the Cambridge Biomedical Campus, one of the largest biomedical hubs in Europe and part of the UK's so-called 'Golden Triangle' of life sciences activity alongside London and Oxford. The move gives GSK scientists direct access to an ecosystem that already combines NHS clinical care, university research, and biotech innovation in one location.

 

To fund the move, GSK will close its long-standing R&D site in Stevenage, Hertfordshire, home to around 1,800 staff, with a phased relocation running through to 2029. Some employees will move to Cambridge; others will transfer to GSK's Ware facility in Hertfordshire, which is being upgraded to support integrated drug development and manufacturing scale-up. GSK has not confirmed exact numbers, but has acknowledged that some roles will be affected by the changes.

GSK's chief executive, Luke Miels, said the investment is designed to accelerate the company's R&D pipeline and help it deliver new, competitive products. GSK already invests more than £6 billion in R&D globally each year, over £1.5 billion of it in the UK.

 

For people working in or looking to move into life sciences, this announcement cuts two ways.

New opportunity in Cambridge. A centre of this scale, housing 1,000+ scientists across oncology, respiratory, hepatology, vaccines, and HIV, will need a wide supporting workforce, not just principal investigators. Likely areas of demand include:

Disruption in Stevenage and Hertfordshire. For the roughly 1,800 people currently based at Stevenage, this is a period of uncertainty. Some roles will transfer to Cambridge, some to Ware, and some may not continue. Anyone affected has several years of lead time given the phased move to 2029, but early planning, whether that's exploring relocation, retraining, or a change of employer, will matter.

For GPs and frontline clinicians more broadly, a larger Cambridge research presence tends to mean more research network involvement and early access programme opportunities over time, particularly for those working in or near the region.

 

This isn't an isolated move. Cambridge Biomedical Campus has drawn major investment from multiple directions in the past two years, including a £400 million government investment announced by the Chancellor to accelerate growth in the city, and a £500 million private-sector expansion from developer Prologis supporting biomedical research space. The campus is estimated to generate £4.2 billion for the UK economy every year, and the co-location of NHS organisations, academic researchers, and industry is precisely what makes it attractive for large-scale R&D investment.

That said, the UK life sciences picture isn't uniformly positive. Other major pharmaceutical investments have been paused or cancelled over the past two years: AstraZeneca halted a planned £200 million Cambridge research facility that had been expected to create 1,000 jobs, and separately shelved a £450 million vaccine plant in Liverpool, while industry body the ABPI has warned that the UK is increasingly being overlooked for pharmaceutical investment. GSK's decision to commit £400 million to Cambridge, while simultaneously closing an established site elsewhere, reflects a broader trend: investment is concentrating in a small number of high-density clusters rather than spreading evenly across the country.

 

For employers, this is a signal to align hiring and messaging with where the growth is happening. Roles connected to oncology, respiratory, hepatology, vaccines, and HIV research, along with the wider clinical and data infrastructure that supports them, are likely to see sustained demand in and around Cambridge over the next few years.

For candidates, particularly those currently based in Stevenage or elsewhere in Hertfordshire, this is a good moment to start exploring options early rather than waiting for formal announcements closer to 2029.

 

How much is GSK investing in Cambridge, and over what period? GSK is investing £400 million over three years to build a new flagship R&D centre on the Cambridge Biomedical Campus.

 

How many jobs will the new GSK Cambridge centre support? The new 300,000 sq ft site is expected to house more than 1,000 GSK scientists, though GSK has not published a full breakdown of new versus relocated roles.

 

Is GSK closing its Stevenage site? Yes. GSK will vacate its Stevenage R&D site, home to around 1,800 staff, with a phased move to Cambridge and Ware running through to 2029. GSK hasn't confirmed how many roles will be affected.

 

What will the new centre focus on? The centre will concentrate on oncology, respiratory disease, hepatology, vaccines, and HIV research.

 

What does this mean for healthcare recruitment in the UK? It points to sustained demand for clinical research, specialist scientific, laboratory, and healthcare data roles in and around Cambridge, alongside disruption for staff currently based in Stevenage.

 

At Work.Healthcare, we track developments like this because they shape where the next wave of healthcare and life sciences hiring will happen. If you're recruiting for research, clinical, or scientific roles connected to this shift, or looking for your next opportunity in the sector, explore current vacancies on Work.Healthcare.